Ceftriaxone treatment
Small molecule
Ceftriaxone treatment is one of 8 small molecule programs targeting Lyme disease. It is currently in development.
1
Indications
2
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Lyme Disease
#DrugCompanyPhaseTrials
1Achromycin V
WWyeth-Lederle Vaccines
Approved
Rocephin
CConrado Roberto Hoffmann Filho
Phase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Antabuse
TevaPhase 2
Antibiotics
MMelinta Therapeutics, Inc.
Phase 3
VLA15
PfizerPhase 3
Psilocybin
COMPASS PathwaysPhase 1
Ceftriaxone treatment
NNantes University Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ceftriaxone treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- NNantes University Hospital